Health Catalyst, a healthcare data analytics company listed on the NASDAQ under the ticker symbol HCAT, is set to release its earnings report this Monday after the market closes. Investors are eagerly anticipating the results to gain insight into the company’s performance and future outlook.
In the previous quarter, Health Catalyst met analysts’ revenue expectations by reporting revenues of $80.72 million, showing a 6.3% increase year-over-year. However, the company’s full-year revenue guidance fell short of analysts’ expectations, raising concerns among investors. Additionally, the revenue guidance for the upcoming quarter also missed expectations, creating uncertainty about the company’s growth trajectory.
Analysts are predicting a 1.8% decline in Health Catalyst’s revenue to $75.01 million for the current quarter, marking a reversal from the 3.5% growth recorded in the same period last year. Adjusted earnings are expected to be around $0.07 per share, indicating a challenging operating environment for the company.
Despite these challenges, analysts covering Health Catalyst have maintained their estimates over the past month, suggesting confidence in the company’s ability to weather the storm. Historically, Health Catalyst has only missed revenue estimates once in the last two years, outperforming expectations by an average of 0.6%.
To provide some context, some of Health Catalyst’s peers in the data analytics sector have already reported their Q3 results. Strategy saw a 10.9% increase in revenue year-over-year, surpassing analysts’ expectations by 9.1%, while Palantir Technologies reported a 62.8% revenue growth, exceeding estimates by 8%. These results offer some insight into the overall performance of the industry and could impact Health Catalyst’s stock price following its earnings release.
In terms of stock performance, investors in the data analytics segment have remained steady in the lead-up to earnings, with share prices remaining relatively flat over the last month. Health Catalyst, however, has seen a 6.8% increase in its stock price during the same period, indicating some optimism among investors.
In conclusion, Health Catalyst’s upcoming earnings report will be closely watched by investors and analysts alike. The company’s ability to meet revenue expectations and provide positive guidance for future quarters will be crucial in determining its long-term growth prospects. Stay tuned for the earnings release to gain a better understanding of Health Catalyst’s performance in the ever-evolving healthcare data analytics industry.
